Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Merger or Acquisition (March 2024)
12 slides from Telix Pharmaceuticals's merger presentation, Mar 5, 2024
Slide 1: ARTMS Inc. Transaction Overview
ARTMS Inc. Transaction Overview 5 March, 2024
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 3: Executive Summary: ARTMS Inc. acquisition
Executive Summary: ARTMS Inc. acquisition Significant advancement in our vertical integration of manufacturing and supply chain About the company Four main areas of commercial synergy • Commercial-stage radioisotope production technology firm, focus Enhanced production capacity of Zirconium, to supp
Slide 4: About the technology
About the technology • Advanced cyclotron-based isotope production • Complete turnkey systems for integration with existing cyclotron systems • Proprietary target platform and consumables enable dramatically higher production yields than competing systems • Current Global validated market forecast p
Slide 5: Building a vertically integrated business
Building a vertically integrated business World-class innovation and manufacturing infrastructure Equipped to deliver Vancouver Liege Continuing to invest Isotope production patient doses globally Quality control in in-house (ARTMS)1 development and ⚫ Global supply chain Herstal production capacity
Slide 6: Introducing QIS
Introducing QIS QUANTM Irradiation System (QIS) can be installed on QUANTM Irradiation System (QIS) most OEM cyclotrons and enables production of desired isotope(s) through use of isotope specific consumable ARTMS has a proprietary and validated isotope irradiation targets production technology leve
Slide 7: Why the ARTMS Platform?
Why the ARTMS Platform? Super-charging radio-metal isotope production ARTMS’ QIS system is ARTMS supplies Desired isotope is isolated and installed on one of many consumables including purified following irradiation, and compatible medical enriched irradiation targets is ready for immediate onsite u
Slide 8: Case study: 68Ga production
Case study: 68Ga production Further differentiates Illuccix® 5000 ARTMS enables rapidly growing Gallium-68 demand at reasonable cost and superior reliability 4500 4000 Reliable high-volume daily isotope production: A single 1 2-hour production run yields >>5000 mCi of 68Ga Gallium-68 yield (mCi) 350
Slide 9: Builds on Illuccix® leading pharmacy distribution strategy
Builds on Illuccix® leading pharmacy distribution strategy Deepens Telix’s strategic pharmacy network relationships in the United States Decentralised production model Projected install base can meet ~95% of U.S. PET scanners Global market forecast to grow by 19% per annum to reach US$35B Global mar
Slide 10: Diagnostic PET/SPECT capabilities
Diagnostic PET/SPECT capabilities Immediate fit with Telix’s leading pipeline 1 2 3 4 • 68Ga: Telix and • 89Zr: All Zircaix® • 99mTc: ARTMS can • 64Cu: No ARTMS have been (TLX250-CDx) address both commercially viable collaborating to zirconium periodic technetium copper production validate ultra-hig
Slide 11: Future frontier: therapeutic radionuclides
Future frontier: therapeutic radionuclides Cyclotron-based production of “next generation isotopes” • Significant advantages over reactor-based production – such as cost, efficiency and waste • Certain high-value and potentially clinically-important isotopes – particularly astatine-211 (211At ) and
Slide 12: Summary
Summary Perfect alignment with Telix’s commercial portfolio, future R&D Further differentiates and empowers Telix’s immediate commercial products Deepens our technology relationship with strategic pharmacy network partners Adds significant production efficiency and cost- effectiveness to Telix’s dec
Telix Pharmaceuticals — Merger or Acquisition (March 2024) on 6ix